{
    "Trade/Device Name(s)": [
        "ACRO HCG Pregnancy Rapid Test"
    ],
    "Submitter Information": "ACRO Biotech, Inc.",
    "510(k) Number": "K172512",
    "Predicate Device Reference 510(k) Number(s)": [
        "K960733"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCX"
    ],
    "Summary Letter Date": "January 12, 2018",
    "Summary Letter Received Date": "January 26, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human chorionic gonadotropin (HCG) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Human Chorionic Gonadotropin (hCG)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        "Lateral flow sandwich immunochromatographic assay"
    ],
    "Methodologies": [
        "Qualitative immunoassay"
    ],
    "Submission Type(s)": [
        "Test",
        "Kit",
        "Device"
    ],
    "Document Summary": "FDA 510(k) summary for ACRO HCG Pregnancy Rapid Test for qualitative detection of human chorionic gonadotropin (hCG) in urine to aid in pregnancy detection.",
    "Indications for Use Summary": "Visual qualitative detection of human chorionic gonadotropin (hCG) in urine as an indication of pregnancy for consumer use.",
    "fda_folder": "Clinical Chemistry"
}